Top Markets
Coin of the day
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
株式のランク #24577
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
株価
$1.48
最終同期: 2025-03-24
時価総額
$59.05M
変化(1日)
0.00%
変化(1年)
0.00%
GB
取引 Achilles Therapeutics plc (ACHL)

カテゴリー

Achilles Therapeutics plc(ACHL)の収益
Aug 2026 時点の収益 TTM: 0
Achilles Therapeutics plc の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Achilles Therapeutics plc の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
$2.23B -
US
- -
CH